Across TCGA pan-cancer cohorts, PIGH Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated PIGH data layer compared with 18 for mass-spec protein and 3 for mass-spec protein.
The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher PIGH Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated PIGH expression acts as an unfavorable survival marker.
OV, SCLC, and PRAD are the cancer types where PIGH Mutation most reproducibly stratifies survival.